Replies to post #122215 on Biotech Values

[genisi]

I assume the hypothesis was based on the observation that C-terminal peptide segments within Abeta(1-40) and Abeta(1-42) have distinct structures, but I think a stronger reason for targeting N-terminus of the Abeta protein was because epitope mapping of sera antibodies isolated from AD patients immunized with the late AN-1792, revealed that the anti Abeta antibodies generated by the vaccine, primarily recognized the N-terminal residues of the peptide.

http://www.ncbi.nlm.nih.gov/pubmed/16130106

This was also observed in mice:

http://www.ncbi.nlm.nih.gov/pubmed/12379850